查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840907

骨質疏鬆症藥物市場（按藥物類別、給藥途徑、劑型、分銷管道、最終用戶和患者性別分類）—2025-2032 年全球預測

Osteoporosis Drugs Market by Drug Class, Route Of Administration, Dosage Form, Distribution Channel, End User, Patient Gender - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨質疏鬆症治療市場將成長至 137.6 億美元，複合年成長率為 5.79%。

主要市場統計數據
基準年2024年 87.7億美元
預計2025年 92.7億美元
預測年份：2032年 137.6億美元
複合年成長率（%） 5.79%

對不斷發展的骨質疏鬆症治療前景的簡明而權威的介紹，整合了相關人員決策的臨床、監管和商業性動態

受科學進步、患者人口結構變化和監管預期不斷演變的驅動，骨質疏鬆症治療領域正經歷一段動態演變時期。本執行摘要總結了影響臨床治療途徑和商業實踐的關鍵進展，為臨床醫生、付款方、製造商和投資者提供了一個討論框架。後續章節重點在於分子生物學創新、多樣化的醫療服務模式以及醫療體系壓力如何重塑治療選擇和相關人員的策略。

隨著人口老化和骨骼健康意識的增強，臨床需求與日益增加的差異化藥物和給藥方式交織在一起。同時，付款人審查和供應鏈漏洞促使製造商重新思考定價、合約和分銷方式。這些因素需要領導者密切關注，以保持競爭力並確保患者獲得藥物。接下來的引言將為深入分析變革性轉變、關稅影響、細分市場細微差別、區域動態、競爭定位、實用建議以及本研究的方法論基礎奠定基礎。

全面檢視快速改變骨質疏鬆症治療方式和治療市場動態的臨床、技術和商業性變革

骨質疏鬆症的診斷、預防和治療方式正在發生重大變革，這些變革正在影響臨床、供應鏈和商業模式。科學創新正在拓展傳統抗骨質疏鬆藥物以外的治療選擇，包括旨在提高療效和療效持久性的新型作用機制和聯合用藥策略。同時，診斷準確性和骨折風險分層的進步正在推動更早的干涉和更個人化的治療流程，進而影響處方模式和縱向照護計畫。

同時，以患者為中心的醫療理念與數位醫療的融合正在增強依從性策略和遠端監控，並在整個醫療過程中創造新的接觸點。製造商正在推出差異化的配方和劑型，以提高耐受性和便利性，而付款人則越來越關注基於價值的合約和實際結果。由於突發的供不應求和全球採購的複雜性，供應鏈最佳化和韌性正成為優先事項。總的來說，這些轉變要求臨床、監管和商業團隊齊心協力，抓住不斷變化的情況帶來的機會。

深入評估近期美國關稅如何改變整個骨質疏鬆症治療生態系統的採購、製造和分銷策略

美國近期的政策發展和貿易行動為藥品採購、籌資策略和生產冗餘，以緩解關稅帶來的成本壓力和潛在延誤。進口關稅可能會改變原料藥和成品藥的投入成本，促使就供應協議和價格調整進行談判，以在不損害患者負擔能力的情況下保持商業性可行性。

醫療保健提供者和付款人也在做出調整，優先考慮國內供應可靠性，探索替代採購途徑，並增加關鍵注射劑和其他劑型的庫存緩衝。由於相關人員需要在供應安全與成本控制之間取得平衡，這些應對措施可能會導致通路利用率和處方行為的暫時變化。此外，監管途徑和海關程序在商業化計劃中變得越來越重要，申辦方將關稅風險評估納入打入市場策略和生命週期管理。最終，關稅變化的累積效應正在加速採購、合約簽訂和分銷實踐的策略調整，凸顯了積極主動的供應鏈管治和相關人員協作參與的必要性。

將治療層級、給藥方式、劑量概況、管道、最終用戶偏好和患者人口統計細微差別與商業策略聯繫起來的細粒度細分洞察

細分分析揭示了不同治療層級、給藥途徑、劑型、分銷管道、最終用戶環境和患者群體之間存在不同的需求模式和營運重點，因此需要製定量身定做的商業化方案。在藥物類別中，市場考慮因素各不相同：雙磷酸鹽類藥物注重長期依從性和成本效益；地Denosumab等單株抗體注重標靶機制和給藥間隔；激素替代療法與更廣泛的內分泌管理相交叉；副甲狀腺素類似物針對合成代謝反應；選擇性雌激素受體調節平衡骨骼和全身效應。這些類別層面的差異會影響臨床定位和訊息。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 硬化蛋白抑制劑在降低老年患者骨折風險的新作用
  • 引入數位健康監測工具來追蹤患者對骨質疏鬆症藥物的依從性
  • Teriparatide biosimilar對現有骨質疏鬆症藥物品牌定價策略的影響
  • 心血管安全性數據更新後的 Romosozumab 臨床結果和市場滲透率
  • 將遺傳風險評估納入個人化骨質疏鬆症治療的決策流程

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：骨質疏鬆症藥物市場（依藥物類別）

  • 雙磷酸鹽
  • Denosumab
  • 荷爾蒙補充療法
  • 副甲狀腺素類似物
  • 選擇性雌激素受體調節

9. 骨質疏鬆症藥物市場（依給藥途徑）

  • 注射
  • 口服

第 10 章骨質疏鬆症治療藥物市場（以劑型）

  • 膠囊
  • 注射
  • 解決方案
  • 藥片

第 11 章骨質疏鬆症藥物市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 12 章骨質疏鬆症藥物市場（依最終使用者）

  • 診所
  • 家庭醫療保健
  • 醫院

第 13 章：骨質疏鬆症藥物市場（依病患性別）

  • 女士
  • 男性

第14章骨質疏鬆症藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章骨質疏鬆症藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章骨質疏鬆症藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • UCB SA
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd
Product Code: MRR-AD36CD8980EF

The Osteoporosis Drugs Market is projected to grow by USD 13.76 billion at a CAGR of 5.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.77 billion
Estimated Year [2025] USD 9.27 billion
Forecast Year [2032] USD 13.76 billion
CAGR (%) 5.79%

A concise authoritative introduction to the evolving osteoporosis treatment environment integrating clinical, regulatory, and commercial dynamics shaping stakeholder decisions

The osteoporosis therapeutic area is undergoing a period of dynamic evolution driven by scientific advances, changing patient demographics, and shifting regulatory expectations. This executive summary synthesizes the critical developments affecting clinical care pathways and commercial practices, framing the discussion for clinicians, payers, manufacturers, and investors. In the following sections, the narrative highlights how molecular innovation, delivery modality diversification, and health-system pressures are collectively reshaping treatment choices and stakeholder strategies.

As the population ages and awareness of bone health increases, clinical demand intersects with a growing pipeline of differentiated agents and delivery forms. Meanwhile, payer scrutiny and supply chain vulnerabilities are prompting manufacturers to rethink pricing, contracting, and distribution approaches. Taken together, these forces warrant close attention from leaders seeking to maintain competitiveness and ensure patient access. The introduction that follows sets the scene for deeper analysis of transformative shifts, tariff effects, segmentation nuances, regional dynamics, competitive positioning, practical recommendations, and methodological foundations supporting the study.

Comprehensive exploration of the seismic clinical, technological, and commercial shifts rapidly transforming osteoporosis care delivery and therapeutic market dynamics

Major transformative shifts are redefining how osteoporosis is diagnosed, prevented, and treated, with implications across clinical practice, supply chains, and commercial models. Scientific innovation has expanded therapeutic options beyond traditional antiresorptives to include novel mechanisms of action and combination strategies that aim to improve efficacy and durability of response. Concurrently, advances in diagnostic precision and fracture risk stratification are leading to earlier intervention and more individualized treatment algorithms, which in turn influence prescribing patterns and long-term care planning.

At the same time, patient-centered care philosophies and digital health integrations are elevating adherence strategies and remote monitoring, creating new touchpoints for engagement across continuum-of-care settings. Manufacturers are responding with differentiated formulations and administration formats to improve tolerability and convenience, while payers are increasingly focused on value-based contracting and real-world outcomes. Supply chain optimization and resilience are emerging as a priority, driven by episodic shortages and global sourcing complexities, prompting a re-evaluation of sourcing, manufacturing footprints, and contingency planning. Altogether, these shifts demand coordinated action across clinical, regulatory, and commercial teams to capture the opportunity presented by the changing landscape.

In-depth assessment of how recent United States tariff measures are reshaping sourcing, manufacturing, and distribution strategies across the osteoporosis therapeutics ecosystem

Recent policy developments and trade measures in the United States have introduced new considerations for pharmaceutical sourcing, pricing, and distribution that ripple through the osteoporosis therapeutic space. Manufacturers that rely on global supply chains have had to reassess procurement strategies and manufacturing redundancy to mitigate tariff-driven cost pressures and potential delays. Import tariffs can alter input costs for active pharmaceutical ingredients and finished dosage forms, prompting negotiations on supply agreements and price adjustments to preserve commercial viability without compromising patient affordability.

Healthcare providers and payers are also adapting by emphasizing domestic supply reliability, exploring alternative sourcing pathways, and increasing inventory buffering for critical injectables and other dosage forms. These responses can lead to temporary shifts in channel utilization and prescribing behavior as stakeholders balance supply certainty with cost containment. Additionally, regulatory pathways and customs procedures have become more salient in commercialization planning, with sponsors integrating tariff risk assessments into market entry strategies and lifecycle management. Ultimately, the cumulative effect of tariff changes is to accelerate strategic realignments across sourcing, contracting, and distribution practices, underscoring the need for proactive supply chain governance and collaborative stakeholder engagement.

Granular segmentation insights connecting therapeutic classes, administration modalities, dosage constructs, channels, end-user settings, and patient demographic nuances to commercial strategy

Segmentation analysis reveals differentiated demand patterns and operational priorities across therapeutic classes, administration routes, dosage formats, distribution channels, end-user settings, and patient demographics, each of which requires tailored commercialization approaches. Based on Drug Class, market considerations vary between Bisphosphonate therapies that emphasize long-term adherence and cost-effectiveness, monoclonal antibody treatments such as Denosumab that focus on targeted mechanisms and administration cadence, Hormone Replacement Therapy offerings that intersect with broader endocrine management, Parathyroid Hormone Analog agents that target anabolic responses, and Selective Estrogen Receptor Modulator options that balance skeletal benefit with systemic effects. These class-level distinctions influence clinical positioning and messaging.

Based on Route Of Administration, injectable products carry different storage, administration, and reimbursement implications compared with oral therapies, necessitating distinct supply chain and patient support models. Based on Dosage Form, the characteristics of capsule, injection, solution, and tablet formats affect patient adherence, manufacturing complexity, and distribution logistics. Based on Distribution Channel, the roles of hospital pharmacies, online pharmacies, and retail pharmacies shape access points, fulfillment strategies, and channel economics. Based on End User, the needs and procurement behaviors of clinics, home healthcare providers, and hospitals differ significantly, shaping packaging, training, and support services. Based on Patient Gender, clinical presentation, risk profiling, and therapeutic preferences may vary between female and male patients, informing engagement, trial design, and real-world evidence generation. Combined, these segmentation lenses guide prioritization of product development, market access pathways, and commercial execution to align with stakeholder expectations.

Strategic regional analysis of divergent healthcare systems, reimbursement landscapes, and adoption drivers influencing osteoporosis therapy access across global regions

Regional dynamics demonstrate clear variations in clinical practice norms, regulatory frameworks, reimbursement mechanisms, and healthcare infrastructure that influence how osteoporosis therapies are adopted and utilized. In the Americas, a pronounced emphasis on value-based care, specialty pharmacy pathways, and payer negotiation shapes formulary access and distribution strategies. Providers in this region increasingly favor interventions that demonstrate measurable outcomes in fracture reduction and adherence support, driving demand for therapies that can be integrated into existing care coordination models.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments create a mosaic of access realities, with some markets characterized by centralized procurement and others by fragmented, local decision making. This complexity necessitates adaptive pricing strategies and robust evidence packages tailored to country-specific HTA and payer expectations. In Asia-Pacific, rapid demographic aging, expanding primary care networks, and growing attention to chronic disease management are elevating demand for both preventive and therapeutic approaches, while local manufacturing capacity and regulatory pathways influence time to market. Across regions, differences in healthcare delivery models, patient engagement channels, and supply chain infrastructure require region-specific commercialization playbooks to optimize uptake and patient outcomes.

Insightful analysis of competitive strategies, partnership models, and innovation pathways that distinguish leading organizations within the osteoporosis therapeutic arena

Competitive positioning among leading pharmaceutical and biotechnology entities reflects diverse approaches to pipeline investment, lifecycle management, and differentiation through formulation and delivery innovations. Some organizations concentrate on incremental enhancements to established mechanisms of action, seeking to optimize dosing intervals, mitigate adverse effects, and improve adherence through patient-centric devices and support programs. Others prioritize first-in-class or best-in-class candidates that address unmet needs in fracture prevention and bone anabolism, leveraging biomarker-driven development and targeted clinical programs to establish clear therapeutic differentiation.

Partnerships and strategic alliances are increasingly common, with companies collaborating across研发, manufacturing, and distribution to accelerate time to market and enhance supply stability. Licensing agreements and co-promotion arrangements allow firms to combine scientific strengths with commercial reach. In parallel, specialty and contract manufacturing organizations play a critical role in ensuring quality and scalability for both injectable biologics and small-molecule dosage forms. Across competitive landscapes, companies that integrate robust real-world evidence generation, patient support services, and payer engagement into commercialization plans are better positioned to achieve sustained clinical adoption and long-term utilization.

Actionable strategic recommendations for manufacturers and stakeholders to fortify supply chains, optimize payer engagement, and accelerate patient-centric adoption of osteoporosis therapies

Industry leaders should prioritize a coherent set of actions that translate strategic intent into measurable outcomes across clinical, commercial, and operational domains. First, invest in resilient supply chain architectures by diversifying suppliers, increasing transparency into upstream inputs, and implementing dual-sourcing or regional manufacturing where feasible to mitigate tariff and disruption risks. Second, align clinical development and real-world evidence programs with payer evidence requirements to facilitate favorable reimbursement conversations and to demonstrate value beyond clinical trial endpoints.

Third, differentiate through patient-centric delivery innovations and adherence-support services that reduce barriers to initiation and persistence, thereby improving long-term outcomes. Fourth, adopt flexible pricing and contracting models, including performance-based arrangements where appropriate, to address payer demands for value while preserving commercial sustainability. Fifth, develop regionally tailored market access strategies that reflect local regulatory, reimbursement, and clinical practice nuances, supported by targeted stakeholder engagement. Finally, cultivate strategic collaborations across the ecosystem-spanning academic centers, specialty pharmacies, and technology providers-to accelerate innovation and expand patient reach. Implementing these recommendations will require cross-functional alignment and disciplined execution to translate insights into competitive advantage.

Rigorous mixed-methods research approach combining stakeholder input, literature synthesis, and scenario analysis to produce reliable strategic insights for osteoporosis therapeutics

The research methodology underpinning this analysis combined multiple qualitative and quantitative evidence streams to ensure robust and actionable conclusions. Primary research included structured interviews and consultations with clinicians, payers, supply chain experts, and commercial leaders to capture firsthand perspectives on clinical practice, procurement challenges, and adoption drivers. Secondary research encompassed regulatory guidance, clinical literature, and public disclosures to contextualize product attributes, safety profiles, and approval pathways. Data triangulation across sources helped validate thematic insights and reduce single-source bias.

Analytical techniques included segmentation mapping, scenario analysis for tariff and supply chain contingencies, and comparative competitive benchmarking to understand differentiation opportunities. Careful attention was paid to the integrity of data sources and the transferability of insights across regions and therapeutic classes. Where appropriate, sensitivity testing of strategic options was conducted to assess robustness under alternative operational assumptions. Together, these methods produced a rigorous evidence base that informs the strategic conclusions and recommendations presented in this executive summary.

Concluding synthesis highlighting strategic imperatives to navigate clinical innovation, payer pressures, and supply chain complexity within the osteoporosis sector

In conclusion, the osteoporosis treatment environment is characterized by meaningful clinical innovation, evolving payer expectations, and heightened supply chain scrutiny, each of which shapes how therapies are developed, accessed, and utilized. Strategic responses that integrate resilient sourcing, differentiated patient-centric value propositions, and payer-aligned evidence generation will be central to achieving durable clinical adoption and commercial success. Regional heterogeneity and segmentation complexity further underscore the need for adaptive, localized strategies coupled with robust global coordination.

Leaders who proactively address tariff-related supply risks, invest in real-world outcomes measurement, and design services that support adherence will be better positioned to meet clinician and patient needs while satisfying payer demands. By executing against the recommended priorities and leveraging collaborative partnerships across the ecosystem, organizations can navigate current headwinds and capitalize on opportunities to improve bone health outcomes at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging role of sclerostin inhibitors in reducing fracture risk among elderly patients
  • 5.2. Adoption of digital health monitoring tools for tracking patient adherence to osteoporosis medications
  • 5.3. Impact of biosimilar teriparatide entry on pricing strategies of established osteoporosis brands
  • 5.4. Clinical outcomes and market uptake of romosozumab following cardiovascular safety data updates
  • 5.5. Integration of genetic risk assessment in personalized osteoporosis treatment decision making processes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoporosis Drugs Market, by Drug Class

  • 8.1. Bisphosphonate
  • 8.2. Denosumab
  • 8.3. Hormone Replacement Therapy
  • 8.4. Parathyroid Hormone Analog
  • 8.5. Selective Estrogen Receptor Modulator

9. Osteoporosis Drugs Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral

10. Osteoporosis Drugs Market, by Dosage Form

  • 10.1. Capsule
  • 10.2. Injection
  • 10.3. Solution
  • 10.4. Tablet

11. Osteoporosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Osteoporosis Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals

13. Osteoporosis Drugs Market, by Patient Gender

  • 13.1. Female
  • 13.2. Male

14. Osteoporosis Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Osteoporosis Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Osteoporosis Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Amgen Inc.
    • 17.3.2. Eli Lilly and Company
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Novartis AG
    • 17.3.5. GlaxoSmithKline plc
    • 17.3.6. Pfizer Inc.
    • 17.3.7. F. Hoffmann-La Roche Ltd
    • 17.3.8. UCB S.A.
    • 17.3.9. AbbVie Inc.
    • 17.3.10. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OSTEOPOROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE ANALOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 268. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 269. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 316. G7 OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 320. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 321. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 324. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 325. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
  • TABLE 330. NATO OSTEOPOROSIS DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY D